According to the results of a post hoc analysis of non-interventional studies (NIS) from different patient populations issued in Dermatology and Therapy, the treatment of psoriasis with the aerosol foam formulation of Calcipotriol/Betamethasone proved to be well-tolerated and effective, offering rapid relief to patients.

Psoriasis, a chronic inflammatory skin condition, poses a substantial burden on individuals requiring long-term therapy. While previous clinical trials have established the efficacy and safety of Calcipotriol/Betamethasone dipropionate foam, this study focused on real-world evidence gathered from 6 NIS conducted across various countries.

Through a meticulous post hoc analysis, data from these NIS were consolidated, providing insights into the effectiveness of this aerosol foam treatment across different regions. The results, based on 1388 patients, reaffirm that 4-weeks use of Calcipotriol/Betamethasone foam is a quick, safe and useful therapy in routine clinical practice for psoriasis.